Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.

Joyce F Liu,Kathryn P Gray,Alexi A Wright,Susana Campos,Panagiotis A Konstantinopoulos,Ariana Peralta,Kimberley MacNeill,Stephanie Morrissey,Christin Whalen,Deborah Dillon,Ursula A Matulonis

Gynecologic Oncology（2019）

引用 25|浏览39

暂无评分

摘要

•Strong pre-clinical rationale supports combining PI3K/AKT and MEK inhibitors in cervical cancer.•The combination of the MEK inhibitor trametinib and the pan-AKT inhibitor GSK2141795 had limited activity.•Major toxicities of the combination included rash, diarrhea, nausea, and ALT elevation.•Alterations in PI3K or RAS signaling did not predict for activity of the combination.

查看译文

关键词

Trametinib,MEK inhibitor,AKT inhibitor,Cervical cancer,Targeted therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要